Tecentriq is a medicine for treating the following cancers:
- urothelial cancer (cancer of the bladder and urinary system)
- lung cancer
- a type of breast cancer known as triple-negative breast cancer.
Tecentriq is used for cancers that are advanced or have spread to other parts of the body either on its own or in combination with other cancer treatments. For urothelial and breast cancers, cancer cells must have a certain amount of a protein called PD-L1. For more information about the use of Tecentriq, see the package leaflet.
Tecentriq contains the active substance atezolizumab.
Tecentriq : EPAR - Medicine overview (PDF/131.94 KB)
First published: 29/09/2017
Last updated: 23/10/2019
Tecentriq : EPAR - Risk-management-plan summary (PDF/289.13 KB)
First published: 23/10/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Roche Registration GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
03/09/2019 Tecentriq - EMEA/H/C/004143 - II/0018; II/0019
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):
- after prior platinum containing chemotherapy, or
- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%.
Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSLCLC should also have received targeted therapy before receiving Tecentriq.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 201901/02/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 201816/11/2018